PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022 On 8thOctober 2014
Summary This Report focuses on "PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022" Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-pharmapoint-neuropathic-pain-global-drug-forecast-and-marketanalysis-to-2022-127508 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Highlights Key Questions Answered - The neuropathic pain market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the neuropathic pain market? - What differences exist in the current disease management across the 3 NP indications, and across the 7 markets? - What are the views of KOLs on the present and future landscape of the neuropathic pain market? - Several brands of neuropathic pain drugs are due for patent expiry. How will the patent expiries impact the neuropathic pain therapeutics market? - The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022?
Key Findings - The main driver for the expansion of the NP market will be the increasing NP incidence due to 2 main reasons: the growing elderly population - And the increase in the prevalence and diagnosis of type 2 diabetes which will lead to growth of the painful diabetic neuropathy (PDN) market - the largest NP segment. - Additionally, the approval of novel formulations and first-in-class therapies in pipeline for NP that will drive sales in this market - The greatest barrier to growth in this market will be the fact that the key market leading drugs will go off patent during the forecast period leading to a NP market largely dominated by generics, which raises the barrier to entry for novel drug therapies.
Scope - Overview of 3 neuropathic pain indications - painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized neuropathic pain therapeutics market revenue, annual cost of therapy and Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
treatment usage pattern data from 2012 and forecast for 10 years to 2022. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the neuropathic pain therapeutics market. - Pipeline analysis: focus on mid to late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs. - Analysis of the current and future market competition in the global neuropathic pain therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. - Develop business strategies by understanding the trends shaping and driving the global neuropathic pain therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neuropathic pain therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global neuropathic pain therapeutics market from 2012-2022. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Other industries we cover: • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
• • • • •
Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Table of Content 2 Introduction 26 2.1 Catalyst 26 2.2 Related Reports 26 3 Disease Overview 27 3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 29 3.1.1 Painful Diabetic Neuropathy 31 3.1.2 Postherpetic Neuralgia 32 3.1.3 Trigeminal Neuralgia 32 3.2 Etiology and Pathophysiology 33 3.2.1 Etiology 34 3.2.2 Pathophysiology 35 4 Epidemiology 43 4.1 Diabetic Neuropathy 43 4.1.1 Disease Background 43 4.1.2 Risk Factors and Comorbidities 44 4.1.3 Global Trends 44 4.1.4 Forecast Methodology 47 4.1.5 Epidemiology Forecast for Diabetic Neuropathy (2012-2022) 57 4.1.6 Discussion 63 4.2 Postherpetic Neuralgia 65 4.2.1 Disease Background 65 4.2.2 Risk Factors and Comorbidities 66 4.2.3 Global Trends 69 4.2.4 Forecast Methodology 75 4.2.5 Epidemiological Forecast for Postherpetic Neuralgia (2012-2022) 84 4.2.6 Discussion 90 4.3 Trigeminal Neuralgia 93 4.3.1 Disease Background 93 4.3.2 Risk Factors and Comorbidities 94 4.3.3 Global Trends 95 4.3.4 Forecast Methodology 97 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
4.3.5 Epidemiological Forecast for Trigeminal Neuralgia (2012-2022) - Incident Cases 102 4.3.6 Epidemiological Forecast for Trigeminal Neuralgia (2012-2022) - Prevalent Cases 108 4.3.7 Discussion 113 5 Disease Management 117 5.1 Diagnosis and Treatment Overview 117 5.1.1 Diagnosis 117 5.1.2 Treatment Overview and Guidelines 124 5.2 US 134 5.2.1 Diagnosis and Referral 134 5.2.2 Drug Treatment 136 5.3 France 138 5.3.1 Diagnosis and Referral 138 5.3.2 Drug Treatment 140 5.4 Germany 142 5.4.1 Diagnosis and Referral 142 5.4.2 Drug Treatment 143 5.5 Italy 145 5.5.1 Diagnosis and Referral 145 5.5.2 Drug Treatment 147 5.6 Spain 148 5.6.1 Diagnosis and Referral 148 5.6.2 Drug Treatment 150 5.7 UK 151 5.7.1 Diagnosis and Referral 151 5.7.2 Drug Treatment 153 5.8 Japan 155 5.8.1 Diagnosis and Referral 155 5.8.2 Drug Treatment 157 6 Competitive Assessment 159 6.1 Overview 159 6.2 Tricyclic Antidepressants 164 6.2.1 Overview 164 6.2.2 Efficacy 165 6.2.3 Safety 166 6.2.4 Forecast 167 6.3 Calcium Channel Alpha-2-Delta Ligands (Anticonvulsants) 169 6.3.1 Overview 169 6.3.2 Efficacy 170 6.3.3 Safety 171 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
6.3.4 Forecast 172 6.3.5 Lyrica 174 6.4 Sodium Channel-Blocking Anticonvulsants (TN) 180 6.4.1 Overview 180 6.4.2 Efficacy 181 6.4.3 Safety 181 6.4.4 Forecast 182 6.5 Serotonin-Norepinephrine Reuptake Inhibitors (Antidepressants) 184 6.5.1 Overview 184 6.5.2 Efficacy 184 6.5.3 Safety 185 6.5.4 Forecast 185 6.5.5 Cymbalta 187 6.6 Opioids 191 6.6.1 Overview 191 6.6.2 Efficacy 191 6.6.3 Safety 192 6.6.4 Forecast 193 6.6.5 Nucynta ER/Palexia SR 195 6.7 Topical Therapies 200 6.7.1 Overview 200 6.7.2 Efficacy 201 6.7.3 Safety 201 6.7.4 Forecast 202 6.7.5 Lidoderm/Versatis 204 6.7.6 Qutenza 209 7 Unmet Need and Opportunity 215 7.1 Overview 215 7.2 Physician Knowledge or Awareness 216 7.2.1 Unmet Need 216 7.2.2 Gap Analysis 217 7.2.3 Opportunity 218 7.3 Diagnostic Challenges 218 7.3.1 Unmet Need 218 7.3.2 Gap Analysis 219 7.3.3 Opportunity 219 7.4 Low Treatment Rate and Underdosing of Medications 219 7.4.1 Unmet Need 219 7.4.2 Gap Analysis 221 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
7.4.3 Opportunity 221 7.5 Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments 222 7.5.1 Unmet Need 222 7.5.2 Gap Analysis 223 7.5.3 Opportunity 223 7.6 Elderly Patient Population - Drug Tolerability 224 7.6.1 Unmet Need 224 7.6.2 Gap Analysis 224 7.6.3 Opportunity 225 7.7 Rational or Personalized Therapies 225 7.7.1 Unmet Need 225 7.7.2 Gap Analysis 226 7.7.3 Opportunity 226 8 Pipeline Assessment 228 8.1 Overview 228 8.2 Clinical Trial Mapping 229 8.2.1 Clinical Trials by Patient Population 229 8.3 Promising Drugs in Clinical Development 232 8.3.1 Eslicarbazepine Acetate 234 8.3.2 Topical Clonidine Gel 241 8.3.3 Cebranopadol 245 8.3.4 DS-5565 249 8.3.5 CNV-2197944 253 8.3.6 CNV-1014802 258 8.3.7 Eladur (bupivacaine patch) 262 9 Current and Future Players 267 9.1 Overview 267 9.2 Trends in Corporate Strategy 269 9.3 Company Profiles 270 9.3.1 Pfizer 270 9.3.2 Eli Lilly 272 9.3.3 Gr端nenthal 274 9.3.4 Endo Health Solutions 277 9.3.5 Janssen Pharmaceuticals 278 9.3.6 Daiichi Sankyo 280 9.3.7 Convergence Pharmaceuticals 282 10 Market Outlook 284 10.1 Global Markets 284 10.1.1 Forecast 284 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
10.1.2 Drivers and Barriers - Global Issues 294 10.2 United States 296 10.2.1 Forecast 296 10.2.2 Key Events 307 10.2.3 Drivers and Barriers 307 10.3 France 310 10.3.1 Forecast 310 10.3.2 Key Events 320 10.3.3 Drivers and Barriers 320 10.4 Germany 322 10.4.1 Forecast 322 10.4.2 Key Events 332 10.4.3 Drivers and Barriers 332 10.5 Italy 335 10.5.1 Forecast 335 10.5.2 Key Events 345 10.5.3 Drivers and Barriers 345 10.6 Spain 347 10.6.1 Forecast 347 10.6.2 Key Events 357 10.6.3 Drivers and Barriers 357 10.7 United Kingdom 359 10.7.1 Forecast 359 10.7.2 Key Events 369 10.7.3 Drivers and Barriers 369 10.8 Japan 371 10.8.1 Forecast 371 10.8.2 Key Events 381 10.8.3 Drivers and Barriers 381 11 Appendix 384 11.1 Bibliography 384 11.2 Abbreviations 403 11.3 Methodology 409 11.4 Forecasting Methodology 409 11.4.1 Diagnosed PDN, PHN, and TN Patients 409 11.4.2 Percent Drug-Treated Patients 410 11.4.3 Drugs Included In Each Therapeutic Class 410 11.4.4 Launch and Patent Expiry Dates 410 11.4.5 General Pricing Assumptions 411 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
11.4.6 Individual Drug Assumptions 412 11.4.7 Generic Erosion 416 11.4.8 Pricing of Pipeline Agents 416 11.5 Physicians and Specialists Included in This Study 417 11.6 About the Authors 419 11.6.1 Author 419 11.6.2 Epidemiologists 420 11.6.3 Global Head of Healthcare 421 11.7 About GlobalData 422 11.8 Disclaimer 422
List Of Tables Table 1: Classification of NP Syndromes Based on the Site of Somatosensory Damage 29 Table 2: Signs and Symptoms of NP 30 Table 3: NP Descriptor Terms 43 Table 4: 7MM, Sources of Diabetic Neuropathy Total Prevalence Data 48 Table 5: 7MM, Excluded Sources of Diabetic Neuropathy Total Prevalence Data 51 Table 6: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, Ages ≥40 Years, N, 2012-2022 58 Table 7: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, by Age, N, Row (%), 2012 59 Table 8: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, by Sex, Ages ≥40 Years, N, Row (%), 2012 61 Table 9: 7MM, Sources of PHN Incidence Data 75 Table 10: 7MM, Incident Cases of PHN, Ages ≥50 Years, Men and Women, N, 2012-2022 84 Table 11: 7MM, Incident Cases of PHN, by Age, Men and Women, N (Row %), 2012 86 Table 12: 7MM, Incident Cases of PHN, by Sex, Ages ≥50 Years, N (Row %), 2012 88 Table 13: Epidemiological Data for TN 96 Table 14: 7MM, Sources of TN Incidence Data 97 Table 15: 7MM, Sources of TN Prevalence Data 97 Table 16: 7MM, Incident Cases of TN, Ages ≥50 Years, Men and Women, N, 2012-2022 103 Table 17: 7MM, Incident Cases of TNa, by Age, Men and Women, N, (Row %), 2012 104 Table 18: 7MM, Incident Cases of TN, by Sex, Ages ≥50 Years, N (Row %), 2012 106 Table 19: 7MM, Prevalent Cases of TN, Ages ≥50 Years, Men and Women, N, 2012-2022 109 Table 20: 7MM, Prevalent Cases of TN, by Age, Men and Women, N, (Row %), 2012 110 Table 21: 7MM, Prevalent Cases of TN, by Sex, Ages ≥50 Years, N (Row %), 2012 112 Table 22: Screening Tools for NP 118 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 23: NP-Related Signs and Symptoms 120 Table 24: Treatment Guidelines for NP 125 Table 25: Recommended Drug Therapies for NP Conditions by Line of Therapy 131 Table 26: Most Prescribed Drugs for NP by Indication and Line of Therapy in the Global Markets, 2012 133 Table 27: US - NP Diagnosis and Referral Metrics 135 Table 28: US - NP Treatment Metrics 138 Table 29: France - NP Diagnosis and Referral Metrics 140 Table 30: France - NP Treatment Metrics 141 Table 31: Germany - NP Diagnosis and Referral Metrics 143 Table 32: Germany - NP Treatment Metrics 145 Table 33: Italy - NP Diagnosis and Referral Metrics 146 Table 34: Italy - NP Treatment Metrics 148 Table 35: Spain - NP Diagnosis and Referral Metrics 149 Table 36: Spain - NP Treatment Metrics 151 Table 37: UK - NP Diagnosis and Referral Metrics 153 Table 38: UK - NP Treatment Metrics 155 Table 39: Japan - NP Diagnosis and Referral Metrics 156 Table 40: Japan - NP Treatment Metrics 158 Table 41: NNT and NNH for Classes of Oral Drugs used in NP Treatment, 2013 161 Table 42: Select Products Used for NP Treatment, 2013 163 Table 43: Global Sales Forecasts ($m) for TCAs, 2012-2022 168 Table 44: Global Sales Forecasts ($m) for Calcium Channel Alpha-2-Delta Ligands, 2012-2022 173 Table 45: Product Profile - Lyrica 175 Table 46: Lyrica SWOT Analysis, 2013 177 Table 47: Global Sales Forecasts ($m) for Lyrica, 2012-2022 179 Table 48: Global Sales Forecasts ($m) for Sodium Channel-Blocking Anticonvulsants, 2012-2022 183 Table 49: Global Sales Forecasts ($m) for SNRIs, 2012-2022 186 Table 50: Product Profile - Cymbalta 187 Table 51: Cymbalta SWOT Analysis, 2013 189 Table 52: Global Sales Forecasts ($m) for Cymbalta, 2012-2022 190 Table 53: Global Sales Forecasts ($m) for Opioids, 2012-2022 194 Table 54: Product Profile - Nucynta ER/Palexia SR 196 Table 55: Nucynta ER/Palexia SR SWOT Analysis, 2013 197 Table 56: Global Sales Forecasts ($m) for Nucynta ER/Palexia SR, 2012-2022 199 Table 57: Global Sales Forecasts ($m) for Topical Therapies, 2012-2022 203 Table 58: Product Profile - Lidoderm/Versatis 205 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 59: Lidoderm/Versatis SWOT Analysis, 2013 206 Table 60: Global Sales Forecasts ($m) for Lidoderm/Versatis, 2012-2022 208 Table 61: Product Profile - Qutenza 210 Table 62: Qutenza SWOT Analysis, 2013 212 Table 63: Global Sales Forecasts ($m) for Qutenza, 2012-2022 214 Table 64: Unmet Need and Opportunity in NP 216 Table 65: NP - Promising Drugs in Clinical Development 232 Table 66: Comparison of Drugs in Development for NP, 2014 233 Table 67: Product Profile - Eslicarbazepine Acetate 235 Table 68: Phase II: Efficacy of Eslicarbazepine Acetate in PHN 236 Table 69: Phase II: Efficacy of Eslicarbazepine Acetate in PDN 236 Table 70: Eslicarbazepine Acetate SWOT Analysis, 2013 238 Table 71: Global Sales Forecasts ($m) for Eslicarbazepine Acetate, 2012-2022 240 Table 72: Product Profile - Topical Clonidine Gel 242 Table 73: Topical Clonidine Gel SWOT Analysis, 2013 244 Table 74: Global Sales Forecasts ($) for Topical Clonidine Gel, 2012-2022 245 Table 75: Product Profile - Cebranopadol 246 Table 76: Cebranopadol SWOT Analysis, 2013 248 Table 77: Global Sales Forecasts ($) for Cebranopadol, 2012-2022 249 Table 78: Product Profile - DS-5565 250 Table 79: DS-5565 SWOT Analysis, 2013 252 Table 80: Global Sales Forecasts ($) for DS-5565, 2012-2022 253 Table 81: Product Profile - CNV-2197944 254 Table 82: CNV-2197944 SWOT Analysis, 2013 256 Table 83: Global Sales Forecasts ($m) for CNV-2197944, 2012-2022 257 Table 84: Product Profile - CNV1014802 259 Table 85: CNV-1014802 SWOT Analysis, 2013 261 Table 86: Global Sales Forecasts ($) for CNV-1014802, 2012-2022 262 Table 87: Product Profile - Eladur 263 Table 88: Eladur SWOT Analysis, 2013 265 Table 89: Global Sales Forecasts ($) for Eladur, 2012-2022 266 Table 90: Key Companies in the NP Market, 2014 268 Table 91: Pfizer’s NP Portfolio Assessment, 2014 271 Table 92: Pfizer SWOT Analysis, 2013 272 Table 93: Eli Lilly’s NP Portfolio Assessment, 2013 273 Table 94: Eli Lilly SWOT Analysis, 2013 274 Table 95: Grünenthal’s NP Portfolio Assessment, 2013 276 Table 96: Grünenthal SWOT Analysis, 2013 276 Table 97: Endo Health Solutions’ NP Portfolio Assessment, 2013 278 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 98: Endo Health Solutions SWOT Analysis, 2013 278 Table 99: Janssen Pharmaceuticals’ NP Portfolio Assessment, 2013 279 Table 100: Janssen Pharmaceuticals SWOT Analysis, 2013 280 Table 101: Daiichi Sankyo’s NP Portfolio Assessment, 2013 281 Table 102: Daiichi Sankyo SWOT Analysis, 2013 282 Table 103: Convergence Pharmaceuticals’ NP Portfolio Assessment, 2013 283 Table 104: Convergence Pharmaceuticals SWOT Analysis, 2013 283 Table 105: Global Sales Forecasts ($) for NP, 2012-2022 286 Table 106: Global Sales Forecasts ($) for PDN, 2012-2022 288 Table 107: Global Sales Forecasts ($) for PHN, 2012-2022 290 Table 108: Global Sales Forecasts ($) for TN, 2012-2022 292 Table 109: NP Market - Drivers and Barriers, 2012-2022 294 Table 110: Sales Forecasts ($) for NP in the United States, 2012-2022 298 Table 111: Sales Forecasts ($) for PDN in the United States, 2012-2022 301 Table 112: Sales Forecasts ($) for PHN in the United States, 2012-2022 303 Table 113: Sales Forecasts ($) for TN in the United States, 2012-2022 305 Table 114: Key Events Impacting Sales for NP in the United States, 2012-2022 307 Table 115: NP Market - Drivers and Barriers in the United States, 2012-2022 307 Table 116: Sales Forecasts ($) for NP in France, 2012-2022 312 Table 117: Sales Forecasts ($) for PDN in France, 2012-2022 314 Table 118: Sales Forecasts ($) for PHN in France, 2012-2022 316 Table 119: Sales Forecasts ($) for TN in France, 2012-2022 318 Table 120: Key Events Impacting Sales for NP in France, 2012-2022 320 Table 121: NP Market- Drivers and Barriers in France, 2012-2022 320 Table 122: Sales Forecasts ($) for NP in Germany, 2012-2022 324 Table 123: Sales Forecasts ($) for PDN in Germany, 2012-2022 326 Table 124: Sales Forecasts ($) for PHN in Germany, 2012-2022 328 Table 125: Sales Forecasts ($) for TN in Germany, 2012-2022 330 Table 126: Key Events Impacting Sales for NP in Germany, 2012-2022 332 Table 127: NP Market - Drivers and Barriers in Germany, 2012-2022 332 Table 128: Sales Forecasts ($) for NP in Italy, 2012-2022 337 Table 129: Sales Forecasts ($) for PDN in Italy, 2012-2022 339 Table 130: Sales Forecasts ($) for PHN in Italy, 2012-2022 341 Table 131: Sales Forecasts ($) for TN in Italy, 2012-2022 343 Table 132: Key Events Impacting Sales for NP in Italy, 2012-2022 345 Table 133: NP Market- Drivers and Barriers in Italy, 2012-2022 345 Table 134: Sales Forecasts ($) for NP in Spain, 2012-2022 349 Table 135: Sales Forecasts ($) for PDN in Spain, 2012-2022 351 Table 136: Sales Forecasts ($) for PHN in Spain, 2012-2022 353 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 137: Sales Forecasts ($) for TN in Spain, 2012-2022 355 Table 138: Key Events Impacting Sales for NP in Spain, 2012-2022 357 Table 139: NP Market- Drivers and Barriers in Spain, 2012-2022 357 Table 140: Sales Forecasts ($) for NP in the UK, 2012-2022 361 Table 141: Sales Forecasts ($) for PDN in the UK, 2012-2022 363 Table 142: Sales Forecasts ($) for PHN in the UK, 2012-2022 365 Table 143: Sales Forecasts ($) for TN in the UK, 2012-2022 367 Table 144: Key Events Impacting Sales for NP in the UK, 2012-2022 369 Table 145: NP Market - Drivers and Barriers in the UK, 2012-2022 369 Table 146: Sales Forecasts ($) for NP in Japan, 2012-2022 373 Table 147: Sales Forecasts ($) for PDN in Japan, 2012-2022 375 Table 148: Sales Forecasts ($) for PHN in Japan, 2012-2022 377 Table 149: Sales Forecasts ($) for TN in Japan, 2012-2022 379 Table 150: Key Events Impacting Sales for NP in Japan, 2012-2022 381 Table 151: NP Market - Drivers and Barriers in Japan, 2012-2022 381 Table 152: Key Launch Dates 410 Table 153: Key Patent/Exclusivity Expiries 411
List Of Figures Figure 1: Nociceptive Versus Neuropathic Pain 28 Figure 2: Etiology and Pathophysiology of NP 33 Figure 3: Pain Pathway - Somatosensory System 36 Figure 4: Pathophysiological Mechanisms of NP at Different Levels of the Nervous System 40 Figure 5: Pathophysiological Targets of NP Drugs 41 Figure 6: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, Ages ≥40 Years, N, 2012-2022 58 Figure 7: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, by Age, N, 2012 60 Figure 8: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, by Sex, Ages ≥40 Years, N, 2012 61 Figure 9: 7MM, Comorbid Hypertension in Diabetic Neuropathy Cases (N), Both Sexes, Ages ≥40, 2012 62 Figure 10: 7MM, Incident Cases of PHN, Ages ≥50 Years, Men and Women, N, 2012-2022 85 Figure 11: 7MM, Incident Cases of PHN, by Age, Men and Women, N, 2012 87 Figure 12: 7MM, Incident Cases of PHN, by Sex, Ages ≥50 Years, N, 2012 88 Figure 13: 7MM, Age-Standardized Incidence of PHN (per 1,000 Population), Ages ≥50 Years, Men and Women, 2012 90 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Figure 14: 7MM, Incident Cases of TN, Ages ≥50 Years, Men and Women, N, 2012-2022 103 Figure 15: 7MM, Incident Cases of TN, by Age, Men and Women, N, 2012 105 Figure 16: 7MM, Incident Cases of TN, by Sex, Ages ≥50 Years, N, 2012 106 Figure 17: 7MM, Age-Standardized Incidence of TN (per 100,000 Population), Ages ≥50 Years, Men and Women, 2012 108 Figure 18: 7MM, Prevalent Cases of TN, Ages ≥50 Years, Men and Women, N, 2012-2022 109 Figure 19: 7MM, Prevalent Cases of TN, by Age, Men and Women, N, 2012 111 Figure 20: 7MM, Prevalent Cases of TN, by Sex, Ages ≥50 Years, N, 2012 112 Figure 21: NeuSPIG Diagnostic Certainty Algorithm for NP 121 Figure 22: General Treatment Algorithm for NP 130 Figure 23: NP Therapeutics - Number of Phase II and III Clinical Trials in Each Indication in the 7MM 230 Figure 24: Competitive Assessment of Mid-to-Late Stage Pipeline Agents in NP, 2012-2022 234 Figure 25: Company Portfolio Gap Analysis in NP, 2012-2022 269 Figure 26: Global Sales for NP by Region, 2012-2022 287 Figure 27: Global Sales for PDN by Drug Class, 2012-2022 289 Figure 28: Global Sales for PHN by Drug Class, 2012-2022 291 Figure 29: Global Sales for TN by Drug Class, 2012-2022 293 Figure 30: Sales for NP in the United States by Drug Class, 2012-2022 300 Figure 31: Sales for PDN in the United States by Drug Class, 2012-2022 302 Figure 32: Sales for PHN in the United States by Drug Class, 2012-2022 304 Figure 33: Sales for TN in the United States by Drug Class, 2012-2022 306 Figure 34: Sales for NP in France by Drug Class, 2012-2022 313 Figure 35: Sales for PDN in France by Drug Class, 2012-2022 315 Figure 36: Sales for PHN in France by Drug Class, 2012-2022 317 Figure 37: Sales for TN in France by Drug Class, 2012-2022 319 Figure 38: Sales for NP in Germany by Drug Class, 2012-2022 325 Figure 39: Sales for PDN in Germany by Drug Class, 2012-2022 327 Figure 40: Sales for PHN in Germany by Drug Class, 2012-2022 329 Figure 41: Sales for TN in Germany by Drug Class, 2012-2022 331 Figure 42: Sales for NP in Italy by Drug Class, 2012-2022 338 Figure 43: Sales for PDN in Italy by Drug Class, 2012-2022 340 Figure 44: Sales for PHN in Italy by Drug Class, 2012-2022 342 Figure 45: Sales for TN in Italy by Drug Class, 2012-2022 344 Figure 46: Sales for NP in Spain by Drug Class, 2012-2022 350 Figure 47: Sales for PDN in Spain by Drug Class, 2012-2022 352 Figure 48: Sales for PHN in Spain by Drug Class, 2012-2022 354 Figure 49: Sales for TN in Spain by Drug Class, 2012-2022 356 Figure 50: Sales for NP in the UK by Drug Class, 2012-2022 362 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Figure 51: Sales for PDN in the UK by Drug Class, 2012-2022 364 Figure 52: Sales for PHN in the UK by Drug Class, 2012-2022 366 Figure 53: Sales for TN in the UK by Drug Class, 2012-2022 368 Figure 54: Sales for NP in Japan by Drug Class, 2012-2022 374 Figure 55: Sales for PDN in Japan by Drug Class, 2012-2022 376 Figure 56: Sales for PHN in Japan by Drug Class, 2012-2022 378 Figure 57: Sales for TN in Japan by Drug Class, 2012-2022 380
Report Price: Licence Type
Price
$ 10995
Site Licence
$ 21990
Enterprise Wide Licence
$ 32985
Related Reports: ContraFect Corporation - Product Pipeline Review - 2014 Five Prime Therapeutics, Inc. - Product Pipeline Review - 2014 PharmaNova Inc. - Product Pipeline Review - 2014 Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 Clarassance, Inc. - Product Pipeline Review - 2014 Morvus Technology Ltd - Product Pipeline Review - 2014 SBI Biotech Co., Ltd. - Product Pipeline Review - 2014 Pharma Mar, S.A. - Product Pipeline Review - 2014 Melior Discovery, Inc. - Product Pipeline Review - 2014 Memgen, LLC. - Product Pipeline Review - 2014
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022 http://www.jsbmarketresearch.com/healthcare-medical/r-pharmapointneuropathic-pain-global-drug-forecast-and-market-analysis-to-2022-127508
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/